DC HEALTHCARE HOLDINGS BERHAD (0283) fair value: what the stock is really worth
As of Nov 6, 2026: fair value (intrinsic value) of DC HEALTHCARE HOLDINGS BERHAD stock MYR 0.06, price MYR 0.08, that is 15.0% below the price, quality 49 out of 100. Rating: overvalued. Calculated from audited financials with 21 of our 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 7, 2026.
How to read this chart
40‑month range 0.0650 MYR – 0.5300 MYR · fair‑value band 0.0413 MYR – 0.0938 MYR · the 0.0750 MYR price screens above the 0.0638 MYR fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 7, 2026.
Follow DC HEALTHCARE HOLDINGS BERHAD in your weekly email
Every Wednesday you see whether DC HEALTHCARE HOLDINGS BERHAD is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
DC Healthcare Holdings Berhad, an investment holding company, provides aesthetic medical services specializing in non-invasive and minimally invasive procedures in Malaysia.
Show moreShow less
The company offers aesthetic services, including facial and skin treatments, facial sculpting, body contouring, and hair growth and removal; and general medical consultation services comprising annual health check-ups and skin disease treatment, as well as sells skincare products to under the newB brand name through online stores.
The company was founded in 2016 and is headquartered in Kuala Puchong, Malaysia. DC Healthcare Holdings Berhad is a subsidiary of DC Healthcare Group Sdn Berhad.
Stock analysis
DC HEALTHCARE HOLDINGS BERHAD (0283) currently trades at 0.0750 MYR, while our model-based Fair Value estimate is 0.0638 MYR, 15% below the price, so the stock looks overvalued today.
Show more
Valuation
Bull case: the Multiples group reads highest at a median of 0.1300 MYR per share, and 5 of the 20 models we run sit above the 0.0750 MYR price.
Bear case: the Earnings-Based group reads lowest at 0.0100 MYR, and 15 of the 20 models stay below the price. Data coverage for this calculation is low.
Scenario range: 0.0413 MYR (bear) to 0.0938 MYR (bull), the price of 0.0750 MYR sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 49/100 (below-average quality), in the Healthcare sector.
Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.
DC HEALTHCARE HOLDINGS BERHAD reported revenue of 87.0M MYR in FY2025 versus 25.5M MYR in FY2021, a compound +35.9%/yr. Reported net income was 206K MYR in FY2025, compounding −54.0%/yr from FY2021.
Key figures
Market cap 74.7M MYR (≈ $18.4M) Micro · P/S ratio 0.70 · Net margin 0.2% · Return on equity 6.0% · Return on assets (EBIT) 8.0% (5-year average) · Operating margin 5.4% · Revenue (TTM) 92.5M MYR · Revenue growth (YoY) +9.8%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 31 out of 100 (low confidence).
What moves the price
The share trades about 56% below its 52-week high and 15% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −1% fair-value upside, at −15%, 0283 screens richer than that median.
Fair Value models
Bear0.0413 MYRFair Value 0.0638 MYRBull0.0938 MYR
Price 0.0750 MYR · Downside -15.0%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.62/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
+55.9%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+18.7%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+43.2%
Start year 2020 (pandemic)
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years), in MYR ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Measured in MYR: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
−42.4%
Earnings growth per share plus dividend.
Earnings per share, growth per year−42.4%
Dividend (yield on the price)0.0%
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.21% → 4%
Growth Forecast
Price in line with expectations
The price assumes about as much growth as the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+46.0%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect
n/a
No analyst forecast available.
After inflation (Malaysia: IMF forecast 2.0% a year to 2030, 1.8% from 2016 to 2025) that is about +43.2% a year for the price.
Compare DC HEALTHCARE HOLDINGS BERHAD with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Care Facilities · 234 stocks
Beats the industry median on 5/12 measures
A mixed picture versus its industry peers.
Valuation
Quality Score49 · Below median
Fair Value upside−14.9% · Below median
Profitability
Return on equity (12 months)6.0% · Below median
Return on assets0.2% · Bottom 25%
Net margin (12 months)2.9% · Below median
Operating margin (12 months)5.4% · Below median
Growth and dividend
Revenue growth (quarter YoY)9.8% · Above median
Balance sheet
Debt / equity0.20× · Below median
Valuation Multiplesvs Medical Care Facilities median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Is DC HEALTHCARE HOLDINGS BERHAD (0283) overvalued or undervalued?
As of Nov 7, 2026, our model estimates a fair value of 0.0638 MYR versus a price of 0.0750 MYR, about 15% lower (overvalued).
What is the fair value of 0283?
Our model-based fair value for DC HEALTHCARE HOLDINGS BERHAD is 0.0638 MYR (as of Nov 7, 2026), built from audited fundamentals. The current price: 0.0750 MYR.
What is the quality score of 0283?
DC HEALTHCARE HOLDINGS BERHAD has a Quality Score of 49/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for DC HEALTHCARE HOLDINGS BERHAD (0283)?
Our model-based price target is the fair value of 0.0638 MYR (as of Nov 7, 2026) from 21 valuation models. Cautious scenario 0.0413 MYR, optimistic scenario 0.0938 MYR. It is a calculation from audited fundamentals, not an analyst target.
What is the DC HEALTHCARE HOLDINGS BERHAD stock forecast for 2026?
Our models put fair value at 0.0638 MYR, about 15% lower versus a price of 0.0750 MYR (overvalued). Cautious scenario 0.0413 MYR, optimistic scenario 0.0938 MYR. The calculation is refreshed regularly with new filings.
What is the revenue of DC HEALTHCARE HOLDINGS BERHAD (0283)?
DC HEALTHCARE HOLDINGS BERHAD reported trailing-twelve-month revenue of about 92.5M MYR (latest available figure, as of Nov 7, 2026).
What growth is priced into DC HEALTHCARE HOLDINGS BERHAD (0283)?
For today's price to be fair in a discounted-cash-flow model, DC HEALTHCARE HOLDINGS BERHAD would have to grow free cash flow by +46.0 % per year for five years (discount rate 9.7 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +43.2 % per year. As of Nov 7, 2026.
What discount rate (WACC) does the fair value of 0283 use?
Our models discount DC HEALTHCARE HOLDINGS BERHAD at 9.7 %: a base by market capitalisation (nano), damped by beta 0.25, country premium for Malaysia. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For DC HEALTHCARE HOLDINGS BERHAD that is +46.0 % per year for five years, then slowing evenly to 2 % by year ten, using the same discount rate (9.7 %) and the same formula as our fair value.
How much growth has DC HEALTHCARE HOLDINGS BERHAD (0283) delivered so far?
Over the past 5 years revenue at DC HEALTHCARE HOLDINGS BERHAD grew +43.2 % a year. The price currently implies free-cash-flow growth of +46.0 % per year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of DC HEALTHCARE HOLDINGS BERHAD (0283) growing?
The median revenue growth in the sector is +6.2 % a year. That is the yardstick for the growth priced into DC HEALTHCARE HOLDINGS BERHAD (+46.0 % per year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of DC HEALTHCARE HOLDINGS BERHAD (0283)?
The free-cash-flow yield on the price is 0.82 %: that much free cash flow DC HEALTHCARE HOLDINGS BERHAD produces per unit of market value. When it exceeds the discount rate of our models (9.7 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of DC HEALTHCARE HOLDINGS BERHAD (0283)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For DC HEALTHCARE HOLDINGS BERHAD it is 0.0638 MYR per share (as of Nov 7, 2026), against a price of 0.0750 MYR. It is the blended result of 21 valuation models in 7 families (DCF Models, Earnings-Based, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings).
Is DC HEALTHCARE HOLDINGS BERHAD stock overvalued or undervalued in 2026?
As of Nov 7, 2026, 0283 trades above its calculated fair value: price 0.0750 MYR, fair value 0.0638 MYR, a gap of about −15% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 0283?
No. The price is what the market pays today (0.0750 MYR); the fair value is what the company's own numbers justify (0.0638 MYR). For DC HEALTHCARE HOLDINGS BERHAD the two are 0.0113 MYR per share apart. That gap is exactly why we show both numbers side by side.
How much is DC HEALTHCARE HOLDINGS BERHAD worth?
The market values DC HEALTHCARE HOLDINGS BERHAD at about 74.7M MYR (market capitalisation, as of Nov 7, 2026). Per share that is 0.0750 MYR; our models calculate a fair value of 0.0638 MYR per share.
What do the bullish and bearish scenarios say about 0283?
Our models span a range for DC HEALTHCARE HOLDINGS BERHAD: cautious scenario 0.0413 MYR, base 0.0638 MYR, optimistic 0.0938 MYR per share (as of Nov 7, 2026, price 0.0750 MYR). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of DC HEALTHCARE HOLDINGS BERHAD (0283)?
Balance-sheet figures for DC HEALTHCARE HOLDINGS BERHAD (as of Nov 7, 2026): return on equity 6.0%, debt of 0.20 per unit of equity. They feed the Quality Score of 49/100, which measures business quality independently of the share price.
How far is 0283 from its 52-week high?
DC HEALTHCARE HOLDINGS BERHAD trades at 0.0750 MYR, about 56% below its 52-week high of 0.1700 MYR and 15% above the low of 0.0650 MYR (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of 0.0638 MYR is for.
Which stocks are comparable to DC HEALTHCARE HOLDINGS BERHAD?
From the same area (Healthcare) we also value HCA Healthcare, Inc, Fresenius SE, Tenet Healthcare Corporation, Dr. Sulaiman Al Habib Medical Services Group, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is DC HEALTHCARE HOLDINGS BERHAD stock attractive at the current price?
The data as of Nov 7, 2026: price 0.0750 MYR, calculated fair value 0.0638 MYR (−15%), Quality Score 49/100, from 21 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 0283 calculated?
We run DC HEALTHCARE HOLDINGS BERHAD through 21 models from 7 families: DCF Models, Earnings-Based, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of 0.0638 MYR builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.3% above its aggregate fair value. DC HEALTHCARE HOLDINGS BERHAD itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of DC HEALTHCARE HOLDINGS BERHAD (0283)?
The closing price on Nov 6, 2026 was 0.0750 MYR. Our model-based fair value is 0.0638 MYR, about 15% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with DC HEALTHCARE HOLDINGS BERHAD right now?
Weak quality (49/100) and above fair value at the same time, the margin of safety is missing on both counts. A fairly wide model range (0.0413 MYR to 0.0938 MYR) leaves room in how you read the outcome. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.
Key figures of DC HEALTHCARE HOLDINGS BERHAD
How large is the market capitalisation of DC HEALTHCARE HOLDINGS BERHAD (0283)?
The market capitalisation of DC HEALTHCARE HOLDINGS BERHAD is 74.7M MYR (≈ $18.4M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of DC HEALTHCARE HOLDINGS BERHAD (0283)?
The price-to-sales ratio of DC HEALTHCARE HOLDINGS BERHAD is 0.70 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What is the net margin of DC HEALTHCARE HOLDINGS BERHAD (0283)?
The net margin of DC HEALTHCARE HOLDINGS BERHAD is 0.2% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of DC HEALTHCARE HOLDINGS BERHAD (0283)?
The return on equity (ROE) of DC HEALTHCARE HOLDINGS BERHAD is 6.0% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of DC HEALTHCARE HOLDINGS BERHAD (0283)?
On an EBIT basis the return on assets of DC HEALTHCARE HOLDINGS BERHAD is 8.0% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of DC HEALTHCARE HOLDINGS BERHAD (0283)?
The operating margin of DC HEALTHCARE HOLDINGS BERHAD is 5.4% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at DC HEALTHCARE HOLDINGS BERHAD (0283)?
Revenue at DC HEALTHCARE HOLDINGS BERHAD is growing +9.8% versus a year earlier (3y avg +18.7%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much net debt does DC HEALTHCARE HOLDINGS BERHAD (0283) carry?
The net debt of DC HEALTHCARE HOLDINGS BERHAD is 3.1M MYR (fiscal year 2025, ≈ 5.1 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch DC HEALTHCARE HOLDINGS BERHAD in the live analysis
One click puts DC HEALTHCARE HOLDINGS BERHAD on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Thin data
Nov 7, 2026